Shilpa Johri, MD
Pulmonary Disease · Richmond, VANPI 1275511719
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (31.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 33.5% of the total. Reporting peaked in 2023 at $15,027 and has fallen 81.3% since, to $2,810 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $64.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$12K
- Merck$9K
- Bayer$8K
- GSK$1K
- AstraZeneca$991
- United Therapeutics Corporation$848
- plus $4K from 30 others
Across 295 payments — averaging $5590.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$801K
- United Therapeutics Corporation$666K
- Bayer$59K
- Janssen Research & Development, LLC$54K
- Boehringer Ingelheim$45K
- Boehringer Ingelheim International GmbH$15K
- plus $10K from 1 others
What the payments were for
- Consulting fees$11,49131%
- Speaking & faculty fees$10,73129%
- Travel & lodging$3,77810%
- Food & beverage$10,74429%
- Education$3431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 67 | $12,420 |
| Merck | 38 | $8,853 |
| Bayer | 38 | $8,060 |
| GSK | 142 | $1,472 |
| AstraZeneca | 36 | $991 |
| United Therapeutics Corporation | 26 | $848 |
| Boehringer Ingelheim | 27 | $486 |
| Grifols USA, LLC | 18 | $412 |
| Sanofi | 22 | $410 |
| Amgen | 21 | $384 |
| Genentech USA, Inc. | 20 | $335 |
| Mallinckrodt Hospital Products Inc. | 11 | $309 |
| Regeneron Healthcare Solutions, Inc. | 16 | $288 |
| Insmed, Inc. | 17 | $272 |
| Novartis | 15 | $252 |
| ANI Pharmaceuticals, Inc. | 7 | $202 |
| Chiesi USA, Inc. | 1 | $132 |
| Pfizer | 7 | $130 |
| Novo Nordisk | 1 | $124 |
| Mylan Specialty L.p. | 7 | $103 |
| Electromed, Inc. | 8 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| Gilead | 5 | $75 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Baxter Healthcare | 3 | $58 |
| Pulmonx Corporation | 2 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Atricure, Inc. | 1 | $26 |
| 3b Medical, Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Verona Pharma, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Sandoz | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,087 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 63 | $1,512,046 |
| AdempasRiociguat | 100 | $1,387,293 |
| Tyvaso DpiTreprostinil | 34 | $818,737 |
| OfevNintedanib Esylate | 28 | $362,487 |
| Ambrisentan | 119 | $345,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 302 | $254,007 |
| OpsumitMacitentan | 18 | $229,568 |
| LetairisAmbrisentan | 13 | $147,244 |
| Tadalafil | 59 | $103,155 |
| Pirfenidone | 11 | $98,283 |
| Breo ElliptaFluticasone/Vilanterol | 180 | $92,350 |
| Spiriva RespimatTiotropium Bromide | 130 | $89,162 |
| SymbicortBudesonide/Formoterol Fumarate | 196 | $64,481 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 108 | $55,951 |
| Dupixent PenDupilumab | 14 | $51,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $12,420 | $1,741,61381 claims |
| BayerAdempas | $8,060 | $1,387,293100 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Jardiance, Combivent Respimat | $486 | $505,600234 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,472 | $419,542647 claims |
| GileadLetairis | $75 | $147,24413 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $991 | $125,489279 claims |
| MerckDulera | $8,853 | $14,82432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Richmond
- Sujoy GillRichmond$296K
- Patricia SimeRichmond$113K
- Apostolos PerelasRichmond$31K
- John SentzRichmond$20K
- Glenn GiesselRichmond$14K
- Nauman ChaudaryRichmond$13K
- Michael MistrettaRichmond$13K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.